Genmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note published on Thursday morning, Benzinga reports. The brokerage currently has a $50.00 price objective on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q2 2024 earnings at $0.30 EPS, Q3 2024 earnings at $0.34 EPS, Q4 2024 earnings at $0.37 EPS and FY2024 earnings at $1.31 EPS.

GMAB has been the subject of several other research reports. BTIG Research upped their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a buy rating in a report on Thursday, June 27th. Morgan Stanley restated an underweight rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Royal Bank of Canada upgraded shares of Genmab A/S from a sector perform rating to an outperform rating in a report on Monday, July 15th. Finally, Truist Financial raised their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a buy rating in a report on Tuesday, June 4th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Hold and a consensus target price of $49.50.

Genmab A/S Trading Up 1.9 %

Genmab A/S stock opened at $27.75 on Thursday. Genmab A/S has a 52 week low of $24.53 and a 52 week high of $42.72. The stock has a market cap of $18.35 billion, a price-to-earnings ratio of 23.13, a PEG ratio of 0.99 and a beta of 0.97. The company’s 50-day moving average price is $27.20 and its two-hundred day moving average price is $28.52.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The business had revenue of $603.30 million during the quarter, compared to analysts’ expectations of $594.23 million. Research analysts expect that Genmab A/S will post 1.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently made changes to their positions in the company. Exchange Traded Concepts LLC lifted its holdings in shares of Genmab A/S by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 3,691 shares of the company’s stock valued at $118,000 after purchasing an additional 936 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Genmab A/S by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock valued at $154,000 after buying an additional 3,770 shares during the period. International Assets Investment Management LLC purchased a new stake in Genmab A/S in the 4th quarter worth about $393,000. Park Place Capital Corp boosted its position in Genmab A/S by 12.3% during the 4th quarter. Park Place Capital Corp now owns 4,891 shares of the company’s stock worth $156,000 after acquiring an additional 535 shares during the period. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Genmab A/S during the 4th quarter valued at about $5,912,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.